company background image
RUA

RUA Life SciencesAIM:RUA Stock Report

Market Cap

UK£31.8m

7D

-3.7%

1Y

-10.3%

Updated

26 Nov, 2021

Data

Company Financials +
RUA fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

RUA Stock Overview

RUA Life Sciences plc, together with its subsidiaries, provides polymers, services, and products to the medical device industry in Europe, the United States, and internationally.

RUA Life Sciences Competitors

Medtronic

NYSE:MDT

US$149.3b

Shanghai MicroPort Endovascular MedTech

SHSE:688016

CN¥20.0b

LifeTech Scientific

SEHK:1302

HK$18.4b

Zylox-Tonbridge Medical Technology

SEHK:2190

HK$8.7b

Price History & Performance

Summary of all time highs, changes and price drops for RUA Life Sciences
Historical stock prices
Current Share PriceUK£1.44
52 Week HighUK£1.80
52 Week LowUK£1.13
Beta1.91
1 Month Change-6.82%
3 Month Change12.99%
1 Year Change-10.31%
3 Year Change187.00%
5 Year Change583.33%
Change since IPO-89.64%

Recent News & Updates

Feb 15
The Rua Life Sciences (LON:RUA) Share Price Is Up 481% And Shareholders Are Delighted

The Rua Life Sciences (LON:RUA) Share Price Is Up 481% And Shareholders Are Delighted

Buying shares in the best businesses can build meaningful wealth for you and your family. And highest quality companies...

Shareholder Returns

RUAGB Medical EquipmentGB Market
7D-3.7%-5.8%-3.0%
1Y-10.3%-9.1%11.7%

Return vs Industry: RUA underperformed the UK Medical Equipment industry which returned -4.3% over the past year.

Return vs Market: RUA underperformed the UK Market which returned 17.9% over the past year.

Price Volatility

Is RUA's price volatile compared to industry and market?
RUA volatility
RUA Average Weekly Movement6.5%
Medical Equipment Industry Average Movement5.1%
Market Average Movement4.8%
10% most volatile stocks in GB Market9.7%
10% least volatile stocks in GB Market2.5%

Stable Share Price: RUA is not significantly more volatile than the rest of UK stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: RUA's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
199632n/ahttps://rualifesciences.com

RUA Life Sciences plc, together with its subsidiaries, provides polymers, services, and products to the medical device industry in Europe, the United States, and internationally. The company operates as a contract developer and manufacturer of medical devices; and licensor of Elast-Eon and ECSil implantable co-polymers that are used in cardiology and urological applications, including pacing leads, cardiac cannulae, and stent devices, as well as reaction injection molding technology for use in high-precision medical device components. It also develops bore polymer sealed grafts and soft tissue patches; and tri leaflet polymeric heart valves.

RUA Life Sciences Fundamentals Summary

How do RUA Life Sciences's earnings and revenue compare to its market cap?
RUA fundamental statistics
Market CapUK£31.84m
Earnings (TTM)-UK£1.45m
Revenue (TTM)UK£1.53m

20.8x

P/S Ratio

-21.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
RUA income statement (TTM)
RevenueUK£1.53m
Cost of RevenueUK£276.00k
Gross ProfitUK£1.25m
ExpensesUK£2.70m
Earnings-UK£1.45m

Last Reported Earnings

Mar 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.065
Gross Margin81.94%
Net Profit Margin-94.96%
Debt/Equity Ratio2.9%

How did RUA perform over the long term?

See historical performance and comparison

Valuation

Is RUA Life Sciences undervalued compared to its fair value and its price relative to the market?

3.74x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate RUA's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate RUA's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: RUA is unprofitable, so we can't compare its PE Ratio to the UK Medical Equipment industry average.

PE vs Market: RUA is unprofitable, so we can't compare its PE Ratio to the UK market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate RUA's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: RUA is overvalued based on its PB Ratio (3.7x) compared to the GB Medical Equipment industry average (3.5x).


Future Growth

How is RUA Life Sciences forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

19.3%

Forecasted Healthcare industry annual growth in earnings


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if RUA's forecast earnings growth is above the savings rate (0.9%).

Earnings vs Market: Insufficient data to determine if RUA's earnings are forecast to grow faster than the UK market

High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if RUA's revenue is forecast to grow faster than the UK market.

High Growth Revenue: Insufficient data to determine if RUA's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if RUA's Return on Equity is forecast to be high in 3 years time


Past Performance

How has RUA Life Sciences performed over the past 5 years?

-45.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: RUA is currently unprofitable.

Growing Profit Margin: RUA is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: RUA is unprofitable, and losses have increased over the past 5 years at a rate of 45.4% per year.

Accelerating Growth: Unable to compare RUA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: RUA is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (97.5%).


Return on Equity

High ROE: RUA has a negative Return on Equity (-17.06%), as it is currently unprofitable.


Financial Health

How is RUA Life Sciences's financial position?


Financial Position Analysis

Short Term Liabilities: RUA's short term assets (£7.3M) exceed its short term liabilities (£1.1M).

Long Term Liabilities: RUA's short term assets (£7.3M) exceed its long term liabilities (£550.0K).


Debt to Equity History and Analysis

Debt Level: RUA has more cash than its total debt.

Reducing Debt: Insufficient data to determine if RUA's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: RUA has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: RUA has sufficient cash runway for 2.1 years if free cash flow continues to reduce at historical rates of 53.7% each year.


Dividend

What is RUA Life Sciences's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate RUA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate RUA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if RUA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if RUA's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of RUA's dividend in 3 years as they are not forecast to pay a notable one for the UK market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.4yrs

Average board tenure


CEO

RUA Life Sciences has no CEO, or we have no data on them.


Board Members

Experienced Board: RUA's board of directors are considered experienced (3.4 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 35.7%.


Top Shareholders

Company Information

RUA Life Sciences plc's employee growth, exchange listings and data sources


Key Information

  • Name: RUA Life Sciences plc
  • Ticker: RUA
  • Exchange: AIM
  • Founded: 1996
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Market Cap: UK£31.835m
  • Shares outstanding: 22.18m
  • Website: https://rualifesciences.com

Number of Employees


Location

  • RUA Life Sciences plc
  • 2 Drummond Crescent
  • Riverside Business Park
  • Irvine
  • Ayrshire
  • KA11 5AN
  • United Kingdom

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/11/26 21:11
End of Day Share Price2021/11/26 00:00
Earnings2021/03/31
Annual Earnings2021/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.